Suchergebnisse - "Oluwole, Olalekan O"

PubPharm (23)

1

Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids

enthalten in: Bone marrow transplantation | 2024

von Oluwole, O. | Forcade, E. | Muñoz, J. | +23

2

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

enthalten in: Blood | 2024

von Neelapu, S. | Chavez, J. | Sehgal, A. | +23

CommentIn: Blood. 2024 Feb 8;143(6):475-476. - PMID 38329775

3

Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States : incorporating longer survival results

enthalten in: Journal of medical economics | 2024

von Oluwole, O. | Ray, M. | Davies, N. | +4

4

An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States

enthalten in: Journal of medical economics | 2024

von Oluwole, O. | Patel, A. | Vadgama, S. | +6

5

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

enthalten in: The New England journal of medicine | 2023

von Westin, J. | Oluwole, O. | Kersten, M. | +129

CommentIn: N Engl J Med. 2023 Sep 21;389(12):1152-1153. - PMID 37733322

6

Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Westin, J. | Locke, F. | Dickinson, M. | +24

7

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

enthalten in: Blood | 2023

von Neelapu, S. | Jacobson, C. | Ghobadi, A. | +27

CommentIn: Blood. 2023 May 11;141(19):2285-2286. - PMID 37166931

8

Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma

enthalten in: Leukemia & lymphoma | 2022

von Oluwole, O. | Chen, J. | Chan, K. | +6

9

Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma : Results from the US Lymphoma CAR-T Consortium

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Jacobs, M. | Jain, M. | Gao, F. | +23

10

Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas

enthalten in: Transplantation and cellular therapy | 2022

von Riedell, P. | Hwang, W. | Nastoupil, L. | +15

CommentIn: Transplant Cell Ther. 2022 Oct;28(10):621-622. - PMID 36202524